Anti Neurofilament L Antibody Market to Register Steady Growth During 2019 – 2029

0
9

Neurofilament is a type of filament that is required for the cytoskeleton of a neuron that supports the axon cytoplasm. The neurofilaments are the most common types of fibrillar component s that are available in the axon. The Neurofilaments are about 3 to 10 times more frequently found than the axonal microtubules. The Neurofilaments are formed of 3 intertwined protofibrils called NF-L, NF-M and NF-H. The NF-L is the neurofilament light or low molecular weight polypeptide and has a molecular weight of 68kDa. Antibodies that bind to NF-L are useful for identifying neuronal cells. In case of neuromas, gangliogliomas, ganglioneuromas, neuroblastomas and ganglioneuroblastomas stain positively for neurofilaments. Paragangliomas, adrenal and extra-adrenal pheochromocytomas, neuroendocrine carcinomas of the skin, carcinoids, and oat cell carcinomas of the lung also express neurofilaments.

The Anti Neurofilament L Antibody is generally used to identify the neurofilaments in the sample using applications such as immunocytochemistry, immunohistochemistry, and western blotting. Some of the companies that offer Anti Neurofilament L Antibody SignalChem, Merck KGaA, Bio-Rad Laboratories, Inc., EnCor Biotechnology Inc., and others.

Download sample copy of this report: 
https://www.futuremarketinsights.com/reports/sample/REP-GB-10138

The Anti Neurofilament L Antibody can be derived form a number of hosts including mice, rabbit, pigs chicken and others. Mouse derived Anti Neurofilament L Antibody are most commonly available. These Anti Neurofilament L Antibody although derived from a specific species they can have cross reactivity with a number of other animals including mice, pigs, rabbits, chicken, human and others.

Anti Neurofilament L Antibody Market: Drivers and Restraints

Rise in R&D investment globally, increase in research activities in Asia Pacific regions, increased activities in neurological research, rise in number of research labs are among the factors that drive the growth of the Anti Neurofilament L Antibody market. However, stringent regulations for research, ethical concerns for use of animals are some of the factors that restrain the growth of the Anti Neurofilament L Antibody market through the forecast period.

Anti Neurofilament L Antibody Market: Overview

The Anti Neurofilament L Antibody market is broadly classified based on host species, applications and end users. Host species include, mouse, rabbit, and others such as pigs and chickens. Based on applications, the Anti Neurofilament L Antibody market can be categorized into immunocytochemistry, immunohistochemistry, western blotting and others. These Anti Neurofilament L Antibody are generally used for research by academic and research institutes, pharma and biotech companies, and contract research organizations.

Anti Neurofilament L Antibody Market: Regional Outlook

Although North America and Europe hold the maximum share in the Anti Neurofilament L Antibody market, Asia Pacific is expected to be an equally lucrative region for the Anti Neurofilament L Antibody market owing to the rise in R&D expenditure, favourable government policies in region such as China and Japan. Thus the Anti Neurofilament L Antibody Market in the Asia Pacific Region is expected to grow at a high CAGR during the forecasted period.

Need more information about Report methodology @ https://www.futuremarketinsights.com/askus/rep-gb-10138

Anti Neurofilament L Antibody Market: Key Players

Some of the Key players in the Anti Neurofilament L Antibody market include, Merck KGaA, BioLegend, Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Bio-Rad Laboratories, Inc., EnCor Biotechnology Inc. among others. Mergers, acquisitions and expansions are the most commonly used strategies by these companies for persistent growth  in the Anti Neurofilament L Antibody market.

LEAVE A REPLY

Please enter your comment!
Please enter your name here